Last reviewed · How we verify

Geriavit (homonicotinic acid)

unknown active

Geriavit (generic name: homonicotinic acid) is a homonicotinic acid drug. It is currently in unknown development.

Geriavit works by binding to the hydroxycarboxylic acid receptor 2, which is involved in various cellular processes.

Geriavit, a homonicotinic acid, is a small molecule targeting the hydroxycarboxylic acid receptor 2. Its mechanism of action is not well-documented, and it is not FDA-approved for any indications. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand Geriavit's potential therapeutic applications and risks. Currently, it is unclear whether Geriavit is patented or available as a generic medication.

At a glance

Generic namehomonicotinic acid
Drug classhomonicotinic acid
TargetHydroxycarboxylic acid receptor 2
Therapeutic areaOther
Phaseunknown

Mechanism of action

Imagine your cells have locks on them, and Geriavit has a key that fits into one of those locks. When it binds, it can influence how the cell behaves, potentially leading to changes in how the body responds to certain conditions. However, the exact details of how this works are still being studied.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Geriavit

What is Geriavit?

Geriavit (homonicotinic acid) is a homonicotinic acid drug.

How does Geriavit work?

Geriavit works by binding to the hydroxycarboxylic acid receptor 2, which is involved in various cellular processes.

What is the generic name of Geriavit?

homonicotinic acid is the generic (nonproprietary) name of Geriavit.

What drug class is Geriavit in?

Geriavit belongs to the homonicotinic acid class. See all homonicotinic acid drugs at /class/homonicotinic-acid.

What development phase is Geriavit in?

Geriavit is in unknown.

What does Geriavit target?

Geriavit targets Hydroxycarboxylic acid receptor 2 and is a homonicotinic acid.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing